BOSTON--(BUSINESS WIRE)--Pyxis Oncology, an immuno-oncology company focused on developing a new family of antibody-based immunotherapies derived from novel insights into the biology of the tumor ...
- Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the ...
Company reports mixed Q1 results with profitability boosted by a large one-time gain from the recent sale of the product tanker "Pyxis Malou". On the flip side, average time charter equivalent ("TCE") ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback